HER2-Positive Breast Cancer

Subcutaneous Pertuzumab Plus Trastuzumab May Optimize Treatment of HER2+ Breast Cancer

January 07, 2020

In an interview with Targeted Oncology at the 2019 San Antonio Breast Cancer Conference, Antionette Tan, MD, shared the results of the FeDEriCa study and explained how the results can impact the treatment of patients with HER2-positive breast cancer in the clinical setting.

European Regulators Approve Adjuvant T-DM1 for Treatment of Patients With HER2+ Breast Cancer

December 31, 2019

Ado-trastuzumab emtansine has been approved by the European Commission for the treatment of adult patients with HER2-positive early breast cancer, in the adjuvant setting who have residual invasive disease after taxane-based chemotherapy and HER2-targeted therapy, in the neoadjuvant setting.1

Tucatinib Developer Seeks FDA Approval for the Treatment of HER2-Positive Breast Cancer

December 23, 2019

Tucatinib developer, Seattle Genetics, Inc., has submitted a new drug application to the FDA for tucatinib in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received at least 3 prior HER2-directed drugs alone or in combination with other drugs, in the neoadjuvant, adjuvant, or metastatic setting, according to a press release.

Adjuvant T-DM1 Leads to Low Recurrence Rates in Patients With Early HER2+ Breast Cancer

December 12, 2019

High rates of disease control were reported in the first set of results from a randomized trial in which adjuvant T-DM1 was compared to trastuzumab and paclitaxel for the treatment of patients with early HER2-positive breast cancer.

Adjuvant Pertuzumab Regimen Improves OS in Patients With HER2+ Early Breast Cancer

December 12, 2019

In the phase III APHINITY trial, pertuzumab with trastuzumab plus chemotherapy demonstrated a 0.9% improvement in overall survival and continued to reduce the risk of disease recurrence in patients with HER2-positive early breast cancer in the adjuvant setting, according to a 6-year analysis of the phase III APHINITY trial presented at the 2019 San Antonio Breast Cancer Symposium.

Later-Line Management of Metastatic Triple Negative Breast Cancer

November 27, 2019

Triple-negative breast cancer — defined as tumors that lack expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 amplification— is a heterogenous disease and clinically represents a major unmet need in the field of oncology. TNBC is associated with aggressive tumor biology and higher risk of recurrence and visceral metastasis, including brain metastasis.

Expert Highlights Emerging Agents for Metastatic HER2+ Breast Cancer

September 16, 2019

In an interview with Targeted Oncology, Charles Geyer, MD, discussed the potential role of neratinib as well as other new agents that are coming down the pipeline for the treatment of patients with metastatic HER2-positive breast cancer. He also addressed the biggest challenges oncologists face in managing this disease.

Explaining PFS2 in the MONALEESA-7 Trial for HR+/HER2- Breast Cancer

July 03, 2019

Debu Tripathy, MD, of the Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, was an investigator in the phase III MONALEESA-7 trial. The purpose of the study was to examine how endocrine therapy, in combination with a cyclin-dependent kinase inhibitor, affects progression-free survival and overall survival in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.

Exploring the Emerging Role of Antibody-Drug Conjugates in TNBC

March 14, 2019

The need for new therapies to treat metastatic triple-negative breast cancer is pressing, and the development of antibody-drug conjugates represents a promising new strategy for these patients, according to Aditya Bardia, MD, MPH.

Stilwill Highlights Benefit of CDK4/6 Inhibitors Across HR+/HER2- Breast Cancer Settings

March 05, 2019

Joseph F. Stilwill, MD, shares insight on the benefit seen with CDK4/6 inhibitors in patients with advanced HR-positive, HER2-negative breast cancer and highlighted ongoing research aimed at overcoming acquired resistance.